Samsara BioCapital

Jade Biosciences is a biopharmaceutical company dedicated to developing innovative therapies for unmet needs in autoimmune diseases. Its lead asset, JADE-001, targets the APRIL pathway for treating IgA nephropathy, with initial clinical trials planned. Additionally, Jade has two preclinical antibody discovery programs, JADE-002 and JADE-003. The company was founded upon assets licensed from Paragon Therapeutics.

Surrozen, Inc. is a clinical-stage biopharmaceutical company based in South San Francisco, California, focused on developing targeted regenerative antibodies to enhance tissue and organ repair in response to serious diseases. Founded in 2015, the company specializes in modulating the Wnt pathway, a crucial mediator of tissue regeneration, through its innovative antibody platforms that target specific organs and tissues. Notable programs include SZN-043, designed to stimulate liver regeneration in both acute and chronic liver diseases, and SZN-1326, aimed at repairing damaged epithelial tissue in patients with inflammatory bowel disease. Surrozen's approach extends to multiple organ systems, with potential applications in the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.

Abcuro develops immunotherapies targeting autoimmunity and cancer. Founded in 2015, the company uses bioinformatics and ex-vivo validation to uncover novel immune system targets.

Normunity is a biotechnology company that develops precision immuno‑oncology medicines, termed immune normalizers, designed to restore the body’s natural immune response against cancer. Leveraging a partnership with Dr. Lieping Chen’s laboratory at Yale School of Medicine, the company focuses on newly discovered mechanisms of immune disruption, such as the exclusion of T‑cells from immune‑sensitive tumors and other barriers to normal immune function. Its pipeline includes programs targeting these mechanisms to enable clinicians to treat cancer by reactivating the patient’s own immunity. Normunity operates from offices in Boston, Massachusetts, and West Haven, Connecticut.

A2 Biotherapeutics, Inc. is a biotechnology company dedicated to developing innovative cell therapies for tumor cancer treatment. Based in Agoura Hills, California, the company utilizes its proprietary Tmod™ platform to create T cell therapies that accurately differentiate between solid tumors and normal cells. This platform allows for the identification and engineering of binders derived from antibodies or T cell receptors, optimizing precision in targeting cancer cells. A2 Biotherapeutics specifically addresses various cancer types, including head, neck, pancreatic, colorectal, and lung cancers, as well as cancer testis antigens. By engineering T cells to recognize genetic material loss in tumors, the company aims to selectively kill tumor cells while sparing healthy tissue. Founded in 2017, A2 Biotherapeutics continues to advance the field of cancer therapy through its innovative approaches.

Ottimo Pharma is a biopharmaceutical company dedicated to developing innovative cancer therapies for solid tumors. Its primary focus is Jankistomig, a bi-functional antibody that simultaneously targets two critical pathways in cancer growth: immune checkpoint inhibition and angiogenesis. By addressing these pathways concurrently, Ottimo Pharma aims to improve treatment outcomes and reduce the burden of cancer on patients and the healthcare system.

Palvella Therapeutics is a biopharmaceutical company founded in 2015 and headquartered in Wayne, Pennsylvania. The company focuses on developing pathogenetically targeted therapies for serious and rare genetic skin diseases that lack approved treatments. Its lead candidate, QTORIN 3.9 % rapamycin anhydrous gel, is built on a patented QTORIN platform and is in late‑stage clinical development for two rare genodermatoses. Palvella’s approach emphasizes addressing the root cause of disease and delivering stable, room‑temperature formulations that penetrate the epidermis and dermis.

Aclaris Therapeutics is a United States-based clinical-stage biopharmaceutical company focused on developing novel therapies for immuno-inflammatory diseases and dermatology, aiming to address unmet medical and aesthetic needs where treatment options are limited. The company operates two segments, therapeutics and contract research, with the therapeutics business pursuing innovative treatments for immuno-inflammatory conditions while the contract research segment provides laboratory services. Its pipeline includes Zunsemetinib, an oral MK2 inhibitor, and ATI-2138, among other drug candidates.

Neurogene is a clinical-stage biotechnology company focused on developing genetic medicines for rare neurological diseases. It leverages its proprietary transgene regulation platform, EXACT, to create gene therapies with the aim of addressing high-need conditions. The company’s pipeline includes NGN-401 for Rett syndrome and NGN-101 for CLN5 Batten disease. Founded in 2018, Neurogene is headquartered in New York and concentrates on advancing therapies that can improve outcomes for patients with limited treatment options.

Alpha9 Theranostics is a biopharma company that focuses on radiotherapeutics for the treatment of solid and hematologic malignancies. The company is creating a strong pipeline of radiopharmaceuticals to target solid and hematologic malignancies. Its systematic approach to radiotherapeutic design is fueled by a toolbox of technologies and chemistries, which offers broad potential for expansion into a multitude of oncology targets. Alpha9 Theranostics was founded in 2019 and is headquartered in Vancouver, Canada.

Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies aimed at addressing significant unmet medical needs in fibrosis, lysosomal storage disorders, and oncology. The company has established a robust pipeline supported by a proprietary discovery engine and a wholly-owned research and development facility. It possesses an extensive library of molecules and a team with considerable expertise in developing compounds that target nuclear receptors, transcription factors, and epigenetic modulation. Inventiva is advancing clinical candidates, including lanifibranor, which is being developed for non-alcoholic steatohepatitis (NASH), a condition currently lacking approved treatments. Additionally, the company is engaged in a variety of pre-clinical therapy programs, further strengthening its portfolio in the fields of oncology, fibrosis, and rare diseases.

OnKure Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that target biologically validated drivers of cancers underserved by existing therapies. The company develops epigenetic therapies, including selective histone deacetylase inhibitors, and advances candidates such as OKI-179 and OKI-422 in preclinical and clinical development. Its approach aims to directly target malignant cells, combine with other targeted therapies, and prime the tumor microenvironment to enhance immunotherapies, with a pipeline of tumor-agnostic candidates designed for optimal efficacy and tolerability.

Enara Bio Limited is a biotechnology company based in Oxford, United Kingdom, specializing in the development of vaccines and immunotherapies for cancer treatment and prevention. Founded in 2016 and previously known as ErVaxx Limited, the company focuses on creating targeted cancer immunotherapies by exploring novel antigens derived from endogenous retroviral DNA sequences. Enara Bio's technology platform enables the identification and assessment of tumor specificity and immunogenic potential, facilitating improved strategies for combating various cancers. Through its innovative approach, the company aims to provide effective therapeutic options for a broad patient population.

Nura Bio is a clinical-stage biopharmaceutical company focused on developing neuroprotective therapies. Its lead drug candidate, NB-4746, inhibits the SARM1 protein to prevent nerve damage in neurological diseases. The company aims to advance this therapy towards phase 1b/2 trials by 2025.

Candid Therapeutics is a biotechnology company specializing in the development of innovative therapies for immunological disorders. The company's primary focus is on creating novel, user-friendly treatments for autoimmune diseases. Their core technology involves advanced T-cell engager antibodies, which precisely redirect T-cells to selectively eliminate autoreactive B-cells, aiming to deliver transformative efficacy and improved therapeutic outcomes for patients.

OrsoBio is a clinical-stage biopharmaceutical company focused on developing therapies for severe metabolic disorders such as diabetes, dyslipidemia, and lipodystrophies. It aims to restore energy homeostasis by targeting pathways relevant to maintaining energy balance.

Founded in Boston in 2016, Elektrofi is a preclinical-stage company focused on revolutionizing drug delivery. Its proprietary formulation system can efficiently process a wide range of therapeutic molecules, including large and complex proteins like monoclonal antibodies.

Pathalys Pharma is a biopharmaceutical company dedicated to developing therapeutics for late-stage chronic kidney diseases. Its primary focus is improving treatment for secondary hyperparathyroidism, an unmet need in healthcare.

Autobahn Therapeutics develops brain-targeting, small molecule therapies for central nervous system disorders. Its lead program ABX-002 is a thyroid hormone receptor beta agonist being developed as an adjunctive treatment for mood disorders, including major depressive disorder and bipolar depression. The company emphasizes precision tuning of CNS exposure, validated clinical and biologic targets, and biomarker-guided development across neuropsychiatry, neurodegeneration, and neuroinflammation to address high unmet medical needs and improve patient outcomes.

CARGO Therapeutics is a clinical-stage biotechnology company developing next-generation CAR T-cell therapies to overcome cancer treatment resistance and access barriers. The company focuses on addressing limitations of approved autologous CAR T therapies, including manufacturing constraints, long turnaround times, and reimbursement challenges, to broaden patient access to potentially curative treatments. Its programs aim to deliver novel solutions that improve cancer treatment outcomes and patient experience. One of its product candidates, CRG-023, is a tri-specific CAR T designed to overcome relapse by targeting multiple B-cell antigens (CD19, CD20, CD22) and addressing mechanisms such as antigen loss, insufficient co-stimulation, and T cell exhaustion.

Founded in 2020, Enlaza Therapeutics is a biotechnology company based in La Jolla, California. It specializes in developing covalent protein therapeutics using a novel synthetic biology platform, aiming to deliver efficacious and safer treatments with prolonged effects and minimal systemic exposure.

Eliem Therapeutics is a clinical-stage biotechnology company focused on developing treatments for nervous system disorders driven by neuronal hyperexcitability. It leverages neuroscience and translational medicine to advance analgesics and other therapies for conditions such as chronic pain, aiming to deliver best-in-class drug candidates that alleviate suffering and improve function. Founded in 2018 and based in Boston, Eliem concentrates on translating scientific insights into clinical solutions to address unmet medical needs in hyperexcitability disorders.

Leap Therapeutics is a clinical-stage biopharmaceutical company focused on developing targeted and immuno-oncology therapeutics. Its primary focus is to advance translational-stage molecules in cell signaling and immuno-oncology areas.

Founded in 2015 and based in Cambridge, Massachusetts, Obsidian Therapeutics develops next-generation controllable cell and gene therapies designed to extend adoptive immunotherapy to every cancer patient. Its innovative approach uses pharmacologic operating systems to precisely control protein activity in cells, enabling physicians to improve upon current cell therapies using simple, safe, orally-active marketed drugs.

Nkarta Therapeutics is a clinical-stage biopharmaceutical company focused on developing allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The company aims to harness the inherent power of NK cells to target and destroy tumor cells, offering a potent and better-tolerated alternative to traditional T-cell therapies for a broad range of cancer indications.

LENZ Therapeutics is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative ophthalmic therapies. It focuses on addressing vision-related issues, particularly presbyopia, which affects the near vision of individuals, especially those over the age of 45. The company's primary product is an aceclidine-based eye drop designed to restore near vision loss associated with this condition. Through its advancements in ophthalmic pharmaceuticals, LENZ Therapeutics aims to improve the quality of life for those impacted by vision challenges.

Alumis is a clinical-stage biopharmaceutical company specializing in precision medicines for autoimmune disorders. It leverages its proprietary precision data analytics platform and expertise in immunology to develop targeted therapies that significantly improve patients' lives.

FogPharma is a biotechnology company focused on developing innovative therapies for cancer treatment through its proprietary cell-penetrating mini proteins (CPMPs). Founded by Greg Verdine, a leader in drug discovery, the company aims to target cancer-causing proteins within cells that are typically inaccessible to traditional drugs. This novel approach allows for the neutralization of these proteins, potentially transforming the treatment landscape for cancer-related diseases. FogPharma collaborates with leading experts in cancer biology and therapy, fostering a network of researchers, investors, and cancer patients dedicated to advancing its mission. The company is committed to delivering this new class of medicines to improve patient outcomes and enhance quality of life for individuals affected by cancer.

vTv Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing orally administered small molecule drug candidates to address unmet medical needs. Its pipeline includes Azeliragon for mild Alzheimer's disease, TTP399 for type 2 diabetes, and other preclinical candidates targeting various diseases.

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for hypertension. The company is advancing its lead product candidate, MLS-101, a highly selective and potent aldosterone synthase inhibitor licensed from Mitsubishi Tanabe Pharma Corporation. Mineralys aims to provide a targeted treatment for patients with uncontrolled hypertension, particularly those who do not achieve adequate blood pressure control despite using multiple antihypertensive medications. By addressing the underlying factors associated with elevated aldosterone levels, Mineralys seeks to improve treatment outcomes for individuals suffering from this condition.

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company based in Menlo Park, California, that specializes in developing therapeutic agents for hematopoietic stem cell transplants and gene therapies. Founded in 2018, the company aims to enhance the safety and efficacy of conditioning agents to broaden the application of curative therapies. Jasper's lead product, JSP191, is a humanized monoclonal antibody currently in clinical development, designed to act as a conditioning agent by selectively clearing hematopoietic stem cells from bone marrow in patients undergoing stem cell transplants. The company also utilizes an engineered hematopoietic stem cells platform to address the limitations of transplant grafts, thereby increasing the accessibility of both allogeneic and autologous gene-edited hematopoietic stem cell therapies for a larger patient population.

Adverum Biotechnologies is a clinical-stage company focused on developing gene therapies to treat ocular diseases. Its pipeline includes ADVM-022 for wet age-related macular degeneration, ADVM-043 for alpha-1 antitrypsin deficiency, and preclinical candidates for other indications.

Syros Pharmaceuticals, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, that specializes in developing innovative treatments for cancer and monogenic diseases through gene control medicines. The company is advancing its lead product candidates, including SY-1425, a selective retinoic acid receptor alpha agonist currently in Phase II clinical trials for specific patient populations with acute myeloid leukemia and myelodysplastic syndrome, and SY-5609, a cyclin-dependent kinase 7 inhibitor under investigation in a Phase I clinical trial for advanced solid tumors. Syros is also engaged in collaborative research, including a partnership with Incyte Corporation aimed at identifying therapeutic targets for myeloproliferative neoplasms and a licensing agreement with TMRC Co. Ltd. for the development of tamibarotene. With a focus on mapping gene regulatory circuits, Syros leverages its proprietary platform and expertise to address significant unmet medical needs in oncology. Founded in 2011, the company aims to establish new standards of care for patients with hematologic malignancies.

Seismic Therapeutic is a biotechnology company focused on advancing immunology drug development through the integration of machine learning in the biologics discovery process. Utilizing its proprietary IMPACT™ platform, Seismic Therapeutic addresses critical challenges in the development of biologics by combining machine learning with structural biology, protein engineering, and translational immunology. This innovative approach aims to create optimized therapies for patients more efficiently. The company is developing a pipeline of biologics specifically targeting adaptive immune system dysregulation to treat various autoimmune diseases.

Eyebiotech is a vision treatment company that develops products to preserve, repair, and improve eyesight. The firm guards against sight-threatening eye disorders and developed the first anti-vascular endothelial growth factor medication for patients with age-related macular degeneration, allowing those with eye ailments to regain their eyesight.

OrsoBio is a clinical-stage biopharmaceutical company focused on developing therapies for severe metabolic disorders such as diabetes, dyslipidemia, and lipodystrophies. It aims to restore energy homeostasis by targeting pathways relevant to maintaining energy balance.

Omniox is a biopharmaceutical company focused on developing innovative treatments for diseases associated with hypoxia, a condition characterized by inadequate oxygen levels in tissues. This lack of oxygen is linked to various serious health issues, including certain cancers and cardiovascular diseases. The company utilizes its proprietary H-NOX platform technology, which is designed to deliver oxygen and nitric oxide specifically to hypoxic tissues. This targeted approach aims to restore normal tissue function and improve patient outcomes by addressing the underlying causes of hypoxia-related diseases. Through its advancements in biologics, Omniox seeks to provide meaningful therapeutic benefits and enable healthcare professionals to develop effective oxygen-based therapies that enhance patient health and recovery.

Tentarix Biotherapeutics is a company focused on developing innovative protein therapeutics that address critical limitations in the treatment of cancer, autoimmune diseases, and other conditions. Utilizing a protein engineering platform, Tentarix specializes in creating multispecific binding molecules that combine unique bioactivities derived from fully human antibody variable domains. By leveraging synthetic biology, the company aims to provide clinicians with new therapeutic options that offer enhanced specificity and activity, thereby improving patient outcomes in various disease contexts.

Abcuro develops immunotherapies targeting autoimmunity and cancer. Founded in 2015, the company uses bioinformatics and ex-vivo validation to uncover novel immune system targets.

Gossamer Bio is a clinical-stage biopharmaceutical company based in San Diego that specializes in the discovery, development, and commercialization of innovative therapeutic products targeting significant unmet medical needs. Founded by former executives from Receptos, the company focuses on areas such as immunology, inflammation, fibrosis, and oncology. Its pipeline includes several promising candidates: Seralutinib, aimed at addressing pulmonary arterial hypertension; GB004, for inflammatory bowel disease; GB1275, targeting various oncology indications; and GB001, designed for moderate-to-severe eosinophilic asthma. Gossamer Bio's strategy involves leveraging a rich in-licensing environment to enhance its therapeutic offerings, supported by a team recognized for their successful track record in drug development.

Septerna is a biotechnology company focused on discovering and developing oral small-molecule medicines that target G protein-coupled receptors (GPCRs). It operates a proprietary Native Complex Platform to accelerate GPCR drug discovery and aims to deliver therapies across endocrinology, immunology and inflammation, and metabolic diseases. The company is advancing a GPCR-focused pipeline with candidates such as SEP-786 (PTH1R) and SEP-631 (MRGPRX2), along with programs targeting TSHR, GLP-1R, GIPR, and GCGR, with the goal of translating GPCR biology into orally available medicines that address unmet patient needs.

Spyglass Pharma specializes in developing innovative treatments for chronic eye diseases using advanced technologies. The company aims to deliver multiple drugs to address additional ophthalmic indications.

Upstream Bio is a clinical-stage biotechnology company focused on developing antibody therapies for severe respiratory disorders. Its lead product, Verekitug, targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine involved in inflammatory responses.

Lyra Therapeutics, Inc. is a clinical-stage therapeutics company dedicated to developing and commercializing innovative drug and delivery solutions for the localized treatment of ear, nose, and throat diseases. The company utilizes its proprietary XTreo technology platform, which allows for the precise and sustained delivery of medications directly to affected tissues through a single administration. Its lead product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed for non-invasive in-office procedures, providing up to six months of continuous drug therapy for chronic rhinosinusitis. The active ingredient in these products is mometasone furoate, known for its established efficacy and safety profile in various FDA-approved medications. Founded in 2005 and headquartered in Watertown, Massachusetts, Lyra Therapeutics aims to improve treatment outcomes for patients suffering from ENT diseases.

Founded in 2017, ElevateBio operates a portfolio of companies focused on developing, manufacturing, and commercializing transformative cell and gene therapies for severe diseases. Through strategic partnerships with leading scientists and inventors, along with a centralized facility for efficient translation of R&D into viable therapies, the company aims to deliver life-changing medicines to patients.

OnKure Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that target biologically validated drivers of cancers underserved by existing therapies. The company develops epigenetic therapies, including selective histone deacetylase inhibitors, and advances candidates such as OKI-179 and OKI-422 in preclinical and clinical development. Its approach aims to directly target malignant cells, combine with other targeted therapies, and prime the tumor microenvironment to enhance immunotherapies, with a pipeline of tumor-agnostic candidates designed for optimal efficacy and tolerability.

CARGO Therapeutics is a clinical-stage biotechnology company developing next-generation CAR T-cell therapies to overcome cancer treatment resistance and access barriers. The company focuses on addressing limitations of approved autologous CAR T therapies, including manufacturing constraints, long turnaround times, and reimbursement challenges, to broaden patient access to potentially curative treatments. Its programs aim to deliver novel solutions that improve cancer treatment outcomes and patient experience. One of its product candidates, CRG-023, is a tri-specific CAR T designed to overcome relapse by targeting multiple B-cell antigens (CD19, CD20, CD22) and addressing mechanisms such as antigen loss, insufficient co-stimulation, and T cell exhaustion.

Abivax is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize immune responses in autoimmune and inflammatory diseases. Its portfolio aims to address large unmet needs across autoimmune conditions, viral infections, and cancer, with obefazimod in Phase 3 trials for adults with moderately to severely active ulcerative colitis, an inflammatory bowel disease. The company relies on its drug development platforms to advance treatments that modulate the immune system and potentially extend benefits to other inflammatory indications.

Palvella Therapeutics is a biopharmaceutical company founded in 2015 and headquartered in Wayne, Pennsylvania. The company focuses on developing pathogenetically targeted therapies for serious and rare genetic skin diseases that lack approved treatments. Its lead candidate, QTORIN 3.9 % rapamycin anhydrous gel, is built on a patented QTORIN platform and is in late‑stage clinical development for two rare genodermatoses. Palvella’s approach emphasizes addressing the root cause of disease and delivering stable, room‑temperature formulations that penetrate the epidermis and dermis.

Alpha9 Theranostics is a biopharma company that focuses on radiotherapeutics for the treatment of solid and hematologic malignancies. The company is creating a strong pipeline of radiopharmaceuticals to target solid and hematologic malignancies. Its systematic approach to radiotherapeutic design is fueled by a toolbox of technologies and chemistries, which offers broad potential for expansion into a multitude of oncology targets. Alpha9 Theranostics was founded in 2019 and is headquartered in Vancouver, Canada.

Founded in 2020, Enlaza Therapeutics is a biotechnology company based in La Jolla, California. It specializes in developing covalent protein therapeutics using a novel synthetic biology platform, aiming to deliver efficacious and safer treatments with prolonged effects and minimal systemic exposure.

immatics is a biopharmaceutical company focused on the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors. The company's customized Adoptive Cell Therapies (ACTengine) and antibody-like TCR Bispecifics are the two main product classes in the pipeline (TCER). With a focus on particularly difficult-to-treat solid malignancies, each therapy modality has unique characteristics to create the desired therapeutic impact for patients at various disease stages and with various types of tumors. immatics biotechnologies was established in 2000 by Hans Rammensee, Harpreet Singh, and Steffen Walter in Tübingen, Baden-Wurttemberg.

Acelyrin is a biopharmaceutical company dedicated to advancing treatments for diseases involving excessive immune system activation. It achieves this by discovering, acquiring, and expediting the development and market launch of innovative drug candidates.

Autobahn Therapeutics develops brain-targeting, small molecule therapies for central nervous system disorders. Its lead program ABX-002 is a thyroid hormone receptor beta agonist being developed as an adjunctive treatment for mood disorders, including major depressive disorder and bipolar depression. The company emphasizes precision tuning of CNS exposure, validated clinical and biologic targets, and biomarker-guided development across neuropsychiatry, neurodegeneration, and neuroinflammation to address high unmet medical needs and improve patient outcomes.

Delfi Diagnostics, Inc. is a biotechnology company based in Baltimore, Maryland, focused on the early detection of cancer through innovative blood tests. Founded in 2018, the company employs artificial intelligence and genome sequencing to identify unique patterns of DNA fragmentation in the blood, enabling the detection of previously unrecognized cancer-associated cell-free DNA fragments. By utilizing machine learning, Delfi Diagnostics aims to develop high-precision, non-invasive blood tests that allow healthcare professionals to detect cancer at its most curable stage, thereby facilitating timely and effective treatment options for patients.

MiroBio Ltd is a biotechnology company based in Oxford, United Kingdom, focused on the development and manufacture of antibody modulators for immune cell receptors, targeting autoimmune diseases. Established in 2018, MiroBio leverages groundbreaking research from the University of Oxford to understand the communication and activation mechanisms of immune cells. The company's innovative platform aims to create antibodies that stimulate specific immune signals, harnessing the body's natural control mechanisms to restore balance within the immune system. By activating these natural processes, MiroBio seeks to provide significant therapeutic benefits for patients suffering from a range of autoimmune conditions, enabling clinicians to better manage and treat these diseases.

Scholar Rock is a biopharmaceutical company dedicated to discovering and developing innovative therapies targeting dysregulated growth factors in disease microenvironments. Its proprietary platform enables the creation of monoclonal antibodies that selectively modulate these proteins at the cellular level, potentially avoiding historical challenges associated with inhibiting growth factors. The company's lead product candidate, SRK-015, is a selective inhibitor of myostatin activation for treating neuromuscular disorders like spinal muscular atrophy.

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for hypertension. The company is advancing its lead product candidate, MLS-101, a highly selective and potent aldosterone synthase inhibitor licensed from Mitsubishi Tanabe Pharma Corporation. Mineralys aims to provide a targeted treatment for patients with uncontrolled hypertension, particularly those who do not achieve adequate blood pressure control despite using multiple antihypertensive medications. By addressing the underlying factors associated with elevated aldosterone levels, Mineralys seeks to improve treatment outcomes for individuals suffering from this condition.

ImmunOs Therapeutics AG is a clinical-stage biotechnology company based in Schlieren, Switzerland, founded in 2014. The company specializes in the discovery and development of innovative immunotherapies aimed at enhancing cancer treatment and addressing autoimmune diseases. ImmunOs focuses on creating novel human immunomodulatory proteins that play a role in both innate and adaptive immunity. Their therapeutics are designed to exert direct anti-tumor effects by remodeling the tumor microenvironment, while also developing antibodies that inhibit the activation of specific HLA molecules linked to autoimmune conditions. Through its research and development efforts, ImmunOs aims to improve the lives of patients facing serious diseases.

Upstream Bio is a clinical-stage biotechnology company focused on developing antibody therapies for severe respiratory disorders. Its lead product, Verekitug, targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine involved in inflammatory responses.

Lyra Therapeutics, Inc. is a clinical-stage therapeutics company dedicated to developing and commercializing innovative drug and delivery solutions for the localized treatment of ear, nose, and throat diseases. The company utilizes its proprietary XTreo technology platform, which allows for the precise and sustained delivery of medications directly to affected tissues through a single administration. Its lead product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed for non-invasive in-office procedures, providing up to six months of continuous drug therapy for chronic rhinosinusitis. The active ingredient in these products is mometasone furoate, known for its established efficacy and safety profile in various FDA-approved medications. Founded in 2005 and headquartered in Watertown, Massachusetts, Lyra Therapeutics aims to improve treatment outcomes for patients suffering from ENT diseases.

Eyebiotech is a vision treatment company that develops products to preserve, repair, and improve eyesight. The firm guards against sight-threatening eye disorders and developed the first anti-vascular endothelial growth factor medication for patients with age-related macular degeneration, allowing those with eye ailments to regain their eyesight.

Seismic Therapeutic is a biotechnology company focused on advancing immunology drug development through the integration of machine learning in the biologics discovery process. Utilizing its proprietary IMPACT™ platform, Seismic Therapeutic addresses critical challenges in the development of biologics by combining machine learning with structural biology, protein engineering, and translational immunology. This innovative approach aims to create optimized therapies for patients more efficiently. The company is developing a pipeline of biologics specifically targeting adaptive immune system dysregulation to treat various autoimmune diseases.

Founded in 2018 and headquartered in Boston, Massachusetts, Dewpoint Therapeutics is a biotechnology company dedicated to researching biomolecular condensates and cellular function. The company aims to develop innovative treatments for various diseases such as cancer, neurodegenerative disorders, immunology, cardiovascular conditions, women's health, and virology.

Septerna is a biotechnology company focused on discovering and developing oral small-molecule medicines that target G protein-coupled receptors (GPCRs). It operates a proprietary Native Complex Platform to accelerate GPCR drug discovery and aims to deliver therapies across endocrinology, immunology and inflammation, and metabolic diseases. The company is advancing a GPCR-focused pipeline with candidates such as SEP-786 (PTH1R) and SEP-631 (MRGPRX2), along with programs targeting TSHR, GLP-1R, GIPR, and GCGR, with the goal of translating GPCR biology into orally available medicines that address unmet patient needs.

Simcha Therapeutics is a biopharmaceutical company focused on developing engineered cytokine immunotherapy for cancer treatment. Founded in 2018 and headquartered in New Haven, Connecticut, the company utilizes directed evolution to create novel cytokines that enhance the immune system's ability to combat diseases. Its lead program, ST-067, is a designer IL-18 cytokine that has demonstrated significant antitumor effects in animal models, both as a standalone treatment and in combination with anti-PD-1 checkpoint inhibitors. This innovative approach aims to provide patients with more effective immunotherapies, thereby improving their ability to fight cancer.

SanReno Therapeutics is a biotechnology company that specializes in the development, manufacturing, and commercialization of therapies for kidney diseases and related conditions. Operating primarily in the People’s Republic of China, Hong Kong, Macau, Taiwan, and Singapore, the company is dedicated to advancing research and development in this therapeutic area. Formed as a joint venture between Chinook Therapeutics, Frazier Healthcare Partners, and Pivotal bioVenture Partners China, SanReno Therapeutics aims to create innovative solutions that enhance the quality of life for patients suffering from kidney-related ailments.

Ablaze Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing Targeted Radiotherapy (TRT) treatments aimed at benefiting cancer patients. The company focuses on innovative TRT products, utilizing the extensive business experience and networks of its founders in cross-border product development and deal-making. By targeting the Chinese market, Ablaze Pharmaceuticals seeks to provide effective cancer treatment options tailored to the needs of patients in the region.

Acelyrin is a biopharmaceutical company dedicated to advancing treatments for diseases involving excessive immune system activation. It achieves this by discovering, acquiring, and expediting the development and market launch of innovative drug candidates.

Tentarix Biotherapeutics is a company focused on developing innovative protein therapeutics that address critical limitations in the treatment of cancer, autoimmune diseases, and other conditions. Utilizing a protein engineering platform, Tentarix specializes in creating multispecific binding molecules that combine unique bioactivities derived from fully human antibody variable domains. By leveraging synthetic biology, the company aims to provide clinicians with new therapeutic options that offer enhanced specificity and activity, thereby improving patient outcomes in various disease contexts.

Science 37 specializes in decentralized clinical trials, offering a technology-driven approach that enables patients to participate from their homes. The company's platform connects researchers with patients via telemedicine investigators and mobile nurses, accelerating trial enrollment and retention while reaching a more diverse patient population.

Exo Therapeutics, Inc. is a drug discovery and development company focused on addressing challenging pharmaceutical targets. Founded in 2018 and based in Cambridge, Massachusetts, the company utilizes its proprietary ExoSight platform to create a pipeline of drug candidates that target exosites, which are unique and distal binding pockets on enzymes. This innovative approach aims to reprogram enzyme activity, leading to precise and effective therapeutic outcomes, particularly in oncology and inflammation, while also minimizing potential side effects for patients. Exo Therapeutics is committed to unlocking breakthrough therapeutics through its team of experienced researchers and a deep understanding of complex disease mechanisms.

Founded in 2015 and based in Cambridge, Massachusetts, Obsidian Therapeutics develops next-generation controllable cell and gene therapies designed to extend adoptive immunotherapy to every cancer patient. Its innovative approach uses pharmacologic operating systems to precisely control protein activity in cells, enabling physicians to improve upon current cell therapies using simple, safe, orally-active marketed drugs.

Alamar Biosciences, founded in 2018 and headquartered in Fremont, California, specializes in developing advanced technologies for the early detection and treatment of cancer and other diseases. The company focuses on a precision proteomics platform that facilitates protein analysis and the creation of antibody technologies. This platform is designed to enhance the diagnosis of diseases, particularly cancer, while also supporting the discovery of new biomarkers. By enabling healthcare providers to detect diseases at an early stage, Alamar Biosciences aims to improve patient outcomes through timely interventions and potential cures.

Attralus, Inc. is a biopharmaceutical company dedicated to addressing the systemic nature of amyloidosis and enhancing the quality of life for affected patients. Incorporated in 2010 and headquartered in South San Francisco, California, Attralus develops proprietary peptide-based pan-amyloid targeting agents aimed at diagnosing and treating various forms and stages of systemic amyloidosis. Its product pipeline includes AT-01, a polybasic peptide radiotracer for diagnostic and monitoring purposes; AT-02, a peptide-immunoglobulin fusion for therapeutic use; and AT-03, an Fc-fusion protein designed for therapeutic applications. By targeting the common pathology present in all systemic amyloidosis diseases, Attralus seeks to create effective treatments for all subtypes, particularly those that currently lack available treatment options. The company was previously known as Aurora Bio, Inc., before rebranding in August 2020.

HilleVax is a clinical-stage biopharmaceutical company headquartered in Boston, Massachusetts, founded in 2021. The company specializes in the development and commercialization of innovative vaccines. Its primary focus is on HIL-214, a virus-like particle (VLP) based vaccine candidate aimed at preventing moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection. HilleVax is dedicated to addressing significant public health challenges through its vaccine initiatives.

Neurogastrx, Inc. is a venture-stage biopharmaceutical company based in Campbell, California, focused on developing innovative therapies for gastrointestinal disorders. Incorporated in 2017, the company specializes in creating products that address unmet medical needs related to the enteric nervous system. One of its lead products, NG101, is designed to enhance gastric motility while also possessing antiemetic properties. Neurogastrx aims to provide effective solutions for functional and motility gastrointestinal disorders, targeting issues related to gut contractions, sensation, and the brain-gut axis, thereby addressing significant patient needs and alleviating disease burdens.

Tango Therapeutics is a biotechnology company focused on developing cancer therapies based on the genetic principle of synthetic lethality. It aims to counteract tumor suppressor gene loss, reverse immune evasion in cancer cells, and identify effective drug combinations.

PepGen Ltd. is a clinical-stage biotechnology company based in Oxford, United Kingdom, focused on advancing the next generation of nucleic acid therapeutics, particularly in the treatment of severe neuromuscular and neurologic diseases. Incorporated in 2018, PepGen has developed its Enhanced Delivery Oligonucleotide (EDO) platform, which is designed to improve the uptake and activity of conjugated oligonucleotide therapeutics. The company's innovative EDO peptides enhance tissue penetration, cellular uptake, and nuclear delivery, demonstrating their ability to transport oligonucleotides effectively into various target tissues, including smooth, skeletal, and cardiac muscle, as well as the central nervous system. PepGen aims to unlock the clinical potential of these transformative therapeutics, with a particular emphasis on the effective delivery of antisense oligonucleotides, and is advancing its novel conjugate therapeutics toward clinical application.

Prime Medicine is a biotechnology company focused on developing genetic therapies using its innovative Prime Editing technology. This next-generation gene editing method allows for precise "search and replace" modifications in the genome, aimed at restoring normal genetic function. The company targets a wide range of diseases with significant unmet medical needs, leveraging the efficiency and versatility of its gene editing capabilities to address the underlying causes of these conditions. Through its commitment to advancing gene editing, Prime Medicine seeks to transform the landscape of genetic medicine.

Abata Therapeutics is a biotechnology company dedicated to developing innovative cell therapies for patients suffering from progressive multiple sclerosis and other severe autoimmune and inflammatory diseases. The company specializes in the manipulation of regulatory T cells (Tregs) to address these conditions, aiming to restore balance within the immune system. By engineering Tregs to precisely target disease-related antigens, Abata Therapeutics creates therapies that can effectively treat diseases such as multiple sclerosis and type 1 diabetes without imposing systemic immune suppression. Founded by experts in immunology and cell therapy, Abata is committed to translating advanced scientific research into meaningful therapies that improve the lives of individuals facing chronic autoimmune challenges.

RayzeBio, Inc. is a biotechnology company based in San Diego, California, founded in 2020. The company specializes in developing tumor-targeted small molecule medicines that leverage radioisotopes to improve cancer treatment outcomes. RayzeBio focuses on creating innovative radiopharmaceuticals, particularly utilizing alpha-emitting radioisotopes like Actinium-225, to target solid tumors effectively. With a robust pipeline of drug candidates, RayzeBio is committed to addressing significant market opportunities in oncology through late-stage clinical programs, development initiatives, and discovery efforts. The company's mission is to provide effective therapeutic solutions aimed at defeating cancer.

Synthekine Inc. is a biotechnology company based in Menlo Park, California, specializing in the development of engineered cytokine therapies and immunotherapies aimed at treating cancer and autoimmune disorders. Founded in 2018, Synthekine utilizes advanced platform technologies, including engineered partial agonists and orthogonal cell therapies, to enhance the efficacy of cytokines while minimizing their toxic side effects. The company's innovative Synthekine Platform employs surrogate agonists instead of traditional mutant cytokines to create selective immunotherapies. Its product pipeline features candidates such as STK-009, an orthogonal ligand paired with SYNCAR-001, an orthogonal receptor-modified CAR-T therapy targeting CD-19. Additionally, Synthekine is developing STK-012, partial agonists of IL-2, and other novel immunotherapies that integrate cytokine receptors to initiate new signaling pathways without relying on wild-type cytokines.

NiKang Therapeutics, Inc. is a biotechnology company established in 2017 and headquartered in Wilmington, Delaware. The company specializes in the discovery and development of small molecule oncology medicines aimed at addressing unmet medical needs in cancer treatment. Utilizing a discovery approach informed by target structure biology, NiKang employs structure-based drug design to facilitate the rapid and efficient development of proprietary drug candidates. This methodology enables the company to create innovative therapies with desirable pharmacological properties, ultimately aimed at improving the lives of patients through enhanced treatment options.

Vedere Bio, Inc. is a biotechnology company based in Cambridge, Massachusetts, established in 2019. The company focuses on developing gene therapy products aimed at restoring functional vision for patients who have experienced vision loss due to Inherited Retinal Degenerations (IRDs) and other causes of vision impairment, both genetic and non-genetic. Unlike many ocular gene therapies that primarily slow the progression of vision loss, Vedere Bio seeks to restore lost vision, regardless of the patient's genetic background or stage of their condition. As of September 2020, Vedere Bio operates as a subsidiary of Novartis AG.

Janux Therapeutics develops immunotherapies that target tumors without harming healthy tissue. Its proprietary technology enables two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr), designed to stimulate the immune system's response against cancer.

Arcellx is a clinical-stage biotechnology company developing immunotherapies and cell therapies for cancer and other serious diseases. It seeks to make cell therapies safer, more effective, and more broadly accessible. Its lead candidate CART-ddBCMA is in a Phase 1 trial for relapsed or refractory multiple myeloma and has FDA Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy designations. The company is also advancing ARC-SparX, a dosable and controllable CAR-T platform, into clinical programs ACLX-001 for relapsed or refractory multiple myeloma and ACLX-002 for relapsed or refractory acute myeloid leukemia. Arcellx's pipeline covers multiple myeloma, acute myeloid leukemia, and other cancer indications, with research extending into additional oncology areas and other serious diseases.

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for hypertension. The company is advancing its lead product candidate, MLS-101, a highly selective and potent aldosterone synthase inhibitor licensed from Mitsubishi Tanabe Pharma Corporation. Mineralys aims to provide a targeted treatment for patients with uncontrolled hypertension, particularly those who do not achieve adequate blood pressure control despite using multiple antihypertensive medications. By addressing the underlying factors associated with elevated aldosterone levels, Mineralys seeks to improve treatment outcomes for individuals suffering from this condition.

Graphite Bio is a clinical-stage gene editing company focused on targeted DNA integration to treat serious diseases. Its platform aims to precisely insert, repair, or replace genetic sequences by integrating therapeutic cargoes at predefined genomic locations, enabling correction of mutations or replacement of disease-causing genes while preserving normal regulatory control. Based in South San Francisco, the company pursues high-efficiency precision gene editing to address underlying causes of disease.

Founded in 2017, ElevateBio operates a portfolio of companies focused on developing, manufacturing, and commercializing transformative cell and gene therapies for severe diseases. Through strategic partnerships with leading scientists and inventors, along with a centralized facility for efficient translation of R&D into viable therapies, the company aims to deliver life-changing medicines to patients.

OnKure Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that target biologically validated drivers of cancers underserved by existing therapies. The company develops epigenetic therapies, including selective histone deacetylase inhibitors, and advances candidates such as OKI-179 and OKI-422 in preclinical and clinical development. Its approach aims to directly target malignant cells, combine with other targeted therapies, and prime the tumor microenvironment to enhance immunotherapies, with a pipeline of tumor-agnostic candidates designed for optimal efficacy and tolerability.

Egenesis Inc. is a biotechnology company focused on gene editing and genome engineering to create human transplantable organs, tissues, and cells. Established in 2015 and headquartered in Cambridge, Massachusetts, with an additional office in New York City, Egenesis aims to address the global organ shortage by developing solid organs and therapeutic cell transplantation solutions for various diseases. The company utilizes a gene editing platform that incorporates techniques such as single-cell cloning and somatic cell nuclear transfer, which are essential for creating human-compatible organ tissues and cells. Egenesis is particularly engaged in advancing programs related to kidney and islet cell transplantation, striving to provide alternative treatment options for patients with life-threatening conditions.

Viracta Therapeutics, Inc. is a clinical-stage drug development company based in Cardiff, California, that specializes in precision oncology focused on virus-associated malignancies. The company utilizes a viral activation therapy platform to develop treatments for cancers linked to the Epstein-Barr Virus (EBV) and other virus-related diseases. Its lead investigational drug, nanatinostat, is being evaluated in combination with the antiviral valganciclovir as a potential oral therapy for EBV-positive lymphoma, including post-transplant lymphoproliferative disorder, plasmablastic lymphoma, and angioimmunoblastic T cell lymphoma. Viracta is also exploring the application of this approach to other EBV-associated conditions, such as nasopharyngeal carcinoma and gastric carcinoma. Founded in 2007 and rebranded from HemaQuest Pharmaceuticals in 2015, Viracta Therapeutics is actively conducting multiple clinical trials to advance its therapeutic candidates.

Centessa Pharmaceuticals is a biopharmaceutical company that focuses on advancing validated drug programs through an asset-centric R&D model. Each program is developed by dedicated subsidiaries, supported by centralized infrastructure and expert management.

Pipeline Therapeutics Inc. is a biotechnology company based in San Diego, California, specializing in the development and commercialization of small molecules aimed at neuroregeneration. Founded in 2017, the company focuses on promoting functional recovery for various neurological disorders. Its lead product candidate, PIPE-505, is a small molecule gamma secretase inhibitor designed to treat mild-to-moderate sensorineural hearing loss associated with cochlear synaptopathy. Additionally, Pipeline Therapeutics has a portfolio of earlier-stage programs, including PIPE-307, which targets remyelination and axonal repair to address conditions like multiple sclerosis. By harnessing the natural repair processes of different nervous system cell types, the company seeks to provide innovative treatments that repair damage within the nervous system.

Notch Therapeutics is a Toronto-based company developing immune cell therapies using induced pluripotent stem cell technology to create gene-edited allogeneic T cells. Its platform enables precise control of Notch signaling during T-cell development, enabling scalable manufacture of a uniform supply of therapeutic T cells for cancer indications such as non-Hodgkin lymphoma, leukemia, and multiple myeloma. The approach aims to overcome bottlenecks in cell therapy development by integrating advanced product design with commercially compatible processes, supporting a next-generation pipeline of cell therapies.

IO Biotech is a clinical-stage biopharmaceutical company focused on developing innovative immune therapies for cancer treatment. Utilizing its unique T-win technology platform, the company creates first-in-class immune-modulating cancer vaccines that aim to activate T cells specific to immune-suppressive molecules. This approach allows for the simultaneous targeting and disruption of multiple pathways that tumors exploit to evade the immune response. IO Biotech has demonstrated a strong capability in advancing its preclinical and clinical candidates, with its two leading compounds targeting IDO and PD-L1 currently in clinical development, while several others are in the preclinical phase.

Delfi Diagnostics, Inc. is a biotechnology company based in Baltimore, Maryland, focused on the early detection of cancer through innovative blood tests. Founded in 2018, the company employs artificial intelligence and genome sequencing to identify unique patterns of DNA fragmentation in the blood, enabling the detection of previously unrecognized cancer-associated cell-free DNA fragments. By utilizing machine learning, Delfi Diagnostics aims to develop high-precision, non-invasive blood tests that allow healthcare professionals to detect cancer at its most curable stage, thereby facilitating timely and effective treatment options for patients.

Abcuro develops immunotherapies targeting autoimmunity and cancer. Founded in 2015, the company uses bioinformatics and ex-vivo validation to uncover novel immune system targets.

Neurogene is a clinical-stage biotechnology company focused on developing genetic medicines for rare neurological diseases. It leverages its proprietary transgene regulation platform, EXACT, to create gene therapies with the aim of addressing high-need conditions. The company’s pipeline includes NGN-401 for Rett syndrome and NGN-101 for CLN5 Batten disease. Founded in 2018, Neurogene is headquartered in New York and concentrates on advancing therapies that can improve outcomes for patients with limited treatment options.